MiRNAs have been demonstrated to be useful in stratifying patients based on MG subgroups (e.g., AChR-MG, MuSK-MG, EOMG, LOMG), as widely discussed above; moreover, the expression levels of some of them were found to change during treatment in relationship with symptom improvements [146]. The gene discussed is MUSK; the disease is myasthenia gravis.